AU Patent

AU2021260721A1 — [1,3]diazino[5,4-d]pyrimidines as HER2 inhibitors

Assigned to Boehringer Ingelheim International GmbH · Expires 2022-09-15 · 4y expired

What this patent protects

The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I), wherein the groups R

USPTO Abstract

The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I), wherein the groups R

Drugs covered by this patent

Patent Metadata

Patent number
AU2021260721A1
Jurisdiction
AU
Classification
—
Expires
2022-09-15
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.